Table 4.

Predictive ability of Week 12 Modified Multiplier of the Simple Endoscopic Score for Crohn’s Disease (MM-SES-CD) versus Simple Endoscopic Score for Crohn’s Disease (SES-CD) on Week 52 endoscopic remission (MM-SES-CD < 22.5) among participants with MM-SES-CD ≥ 22.5 at baseline (n = 100).

Endoscopic remission at Week 12	AUC (95% CI)
	Overall (n = 100)	Adalimumab (n = 51)	Placebo (n = 49)
Absence of mucosal ulcerations	0.62 (0.57-0.67)	0.63 (0.56-0.69)	0.61 (0.54-0.68)
SES-CD of 0	0.54 (0.51-0.57)	0.55 (0.51-0.60)	0.52 (0.49-0.55)
SES-CD < 3	0.56 (0.52-0.59)	0.58 (0.53-0.64)	0.52 (0.49-0.55)
SES-CD < 4	0.61 (0.56-0.65)	0.66 (0.59-0.72)	0.53 (0.49-0.57)
MM-SES-CD < 22.5	0.71 (0.60-0.81)	0.67 (0.33-1.00)	0.68 (0.55-0.81)
MM-SES-CD ≥ 20% reduction from baseline	0.73 (0.62-0.84)	0.72 (0.39-1.00)	0.69 (0.56-0.83)
MM-SES-CD ≥ 40% reduction from baseline	0.69 (0.59-0.80)	0.67 (0.33-1.00)	0.65 (0.52-0.77)
SES-CD ≥ 50% reduction from baseline	0.62 (0.51-0.72)	0.60 (0.27-0.94)	0.55 (0.43-0.67)